JP2017535284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535284A5 JP2017535284A5 JP2017543315A JP2017543315A JP2017535284A5 JP 2017535284 A5 JP2017535284 A5 JP 2017535284A5 JP 2017543315 A JP2017543315 A JP 2017543315A JP 2017543315 A JP2017543315 A JP 2017543315A JP 2017535284 A5 JP2017535284 A5 JP 2017535284A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- antigen
- apc
- car polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 30
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 230000002438 mitochondrial effect Effects 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 108700008625 Reporter Genes Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 230000005754 cellular signaling Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 239000012642 immune effector Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 230000025608 mitochondrion localization Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 101100065514 Mus musculus Eral1 gene Proteins 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075667P | 2014-11-05 | 2014-11-05 | |
| US201462075642P | 2014-11-05 | 2014-11-05 | |
| US201462075561P | 2014-11-05 | 2014-11-05 | |
| US62/075,561 | 2014-11-05 | ||
| US62/075,667 | 2014-11-05 | ||
| US62/075,642 | 2014-11-05 | ||
| US201562169979P | 2015-06-02 | 2015-06-02 | |
| US62/169,979 | 2015-06-02 | ||
| PCT/US2015/059293 WO2016073755A2 (en) | 2014-11-05 | 2015-11-05 | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019203260A Division JP2020022504A (ja) | 2014-11-05 | 2019-11-08 | 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535284A JP2017535284A (ja) | 2017-11-30 |
| JP2017535284A5 true JP2017535284A5 (OSRAM) | 2018-12-13 |
Family
ID=54548288
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543315A Withdrawn JP2017535284A (ja) | 2014-11-05 | 2015-11-05 | 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 |
| JP2019203260A Pending JP2020022504A (ja) | 2014-11-05 | 2019-11-08 | 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019203260A Pending JP2020022504A (ja) | 2014-11-05 | 2019-11-08 | 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20170333480A1 (OSRAM) |
| EP (2) | EP3215535A2 (OSRAM) |
| JP (2) | JP2017535284A (OSRAM) |
| KR (1) | KR20170075785A (OSRAM) |
| CN (1) | CN107207615A (OSRAM) |
| AU (2) | AU2015343013B2 (OSRAM) |
| CA (1) | CA2964785A1 (OSRAM) |
| HK (1) | HK1243441A1 (OSRAM) |
| WO (1) | WO2016073755A2 (OSRAM) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| KR102238226B1 (ko) | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| AU2015218239B2 (en) | 2014-02-14 | 2019-01-31 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| CN106459914B (zh) | 2014-05-15 | 2020-11-06 | 新加坡国立大学 | 经修饰的自然杀伤细胞及其用途 |
| WO2016073629A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| PT3240805T (pt) | 2014-12-15 | 2025-01-28 | Univ California | Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP3261656B1 (en) | 2015-02-24 | 2020-08-19 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| PL3268470T3 (pl) | 2015-03-11 | 2021-06-14 | Board Of Regents, The University Of Texas System | Polipeptydy transpozazy i ich zastosowania |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| HK1258218A1 (zh) | 2015-09-15 | 2019-11-08 | Board Of Regents, The University Of Texas System | T細胞受體(tcr)結合抗體及其應用 |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CN110191898B (zh) | 2016-06-08 | 2024-05-10 | 英特瑞克斯顿股份有限公司 | Cd33特异性嵌合抗原受体 |
| CN106117366A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种cd19特异性嵌合抗原受体及其编码基因、应用 |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| AU2017352591B2 (en) | 2016-11-07 | 2024-07-11 | Genovie Ab | A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells |
| EP4332226A3 (en) * | 2016-11-07 | 2024-05-08 | Genovie AB | An engineered two-part cellular device for discovery and characterisation of t-cell receptor interaction with cognate antigen |
| KR102833088B1 (ko) * | 2016-11-07 | 2025-07-10 | 제노비에 에이비 | T-세포 수용체 및 t-세포 항원의 식별 및 특징규명을 위한 조작된 다성분 시스템 |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN118406655A (zh) | 2017-01-10 | 2024-07-30 | 普瑞赛格恩公司 | 通过新基因开关表达系统调节多肽的表达 |
| CN108424458A (zh) * | 2017-02-13 | 2018-08-21 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的嵌合抗原受体及其用途 |
| EP3589295B1 (en) | 2017-02-28 | 2024-09-11 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| MX2019011514A (es) | 2017-03-27 | 2020-01-27 | Nat Univ Singapore | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. |
| CN110494557A (zh) | 2017-03-27 | 2019-11-22 | 新加坡国立大学 | 用于离体扩增和活化自然杀伤细胞的刺激细胞系 |
| ES2905377T3 (es) * | 2017-04-18 | 2022-04-08 | Autolus Ltd | Célula |
| CN110997920A (zh) | 2017-06-07 | 2020-04-10 | 英特拉克森公司 | 新型细胞标签的表达 |
| TW201908335A (zh) * | 2017-07-25 | 2019-03-01 | 美國德州系統大學評議委員會 | 增強之嵌合抗原受體及其用途 |
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| KR102809909B1 (ko) * | 2017-09-29 | 2025-05-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 |
| EP3710471A1 (en) * | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| CN108103106A (zh) * | 2018-01-09 | 2018-06-01 | 河南省华隆生物技术有限公司 | 一种pFTM3GW重组载体及其制备方法和应用 |
| CA3089319A1 (en) * | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| CN110093351B (zh) * | 2018-01-29 | 2023-06-23 | 华南生物医药研究院 | 可分离的核酸、多肽、重组载体、重组细胞及应用 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CA3090512A1 (en) | 2018-02-09 | 2019-08-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| WO2019182425A1 (ko) * | 2018-03-23 | 2019-09-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| CA3103610A1 (en) * | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| EP3815711A4 (en) * | 2018-06-29 | 2022-08-10 | Taiho Pharmaceutical Co., Ltd. | ANTITUMOR AGENT AND ITS METHOD OF EVALUATION |
| CN112513256A (zh) | 2018-07-13 | 2021-03-16 | 国立大学法人京都大学 | γδT细胞的制造方法 |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| EP3847266A1 (en) * | 2018-09-05 | 2021-07-14 | GlaxoSmithKline Intellectual Property Development Ltd | T cell modification |
| TW202031679A (zh) * | 2018-10-26 | 2020-09-01 | 日商橘生藥品工業股份有限公司 | 高效率之基因改造細胞之製作方法 |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| KR20220030205A (ko) * | 2019-02-08 | 2022-03-10 | 디앤에이 투포인토 인크. | 면역 세포의 트랜스포존 기반 변형 |
| CN111544585B (zh) * | 2019-02-11 | 2024-12-27 | 北京卡替医疗技术有限公司 | 一种可助推免疫细胞在体内扩增的佐剂 |
| WO2020178738A1 (en) * | 2019-03-04 | 2020-09-10 | University Health Network | T cell receptors and methods of use thereof |
| EP3935176A4 (en) | 2019-03-04 | 2022-12-28 | University Health Network | T-CELL RECEPTORS AND METHODS OF USE THEREOF |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN113710688A (zh) * | 2019-03-26 | 2021-11-26 | 加利福尼亚大学董事会 | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) |
| WO2021019706A1 (ja) * | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| CN110592014A (zh) * | 2019-08-14 | 2019-12-20 | 广东美赛尔细胞生物科技有限公司 | 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法 |
| WO2021100585A1 (ja) * | 2019-11-20 | 2021-05-27 | 国立大学法人東海国立大学機構 | キメラ抗原受容体遺伝子改変リンパ球の調製方法 |
| GB201918908D0 (en) * | 2019-12-19 | 2020-02-05 | Autolus Ltd | Cell |
| CN111264469B (zh) * | 2020-02-27 | 2022-03-25 | 西安交通大学医学院第一附属医院 | 一种基因免疫诱导的甲状腺相关性眼病动物模型的构建方法及雷帕霉素类药物的应用 |
| EP4127141A1 (en) * | 2020-04-03 | 2023-02-08 | Cellvie Inc. | Enhancement of adoptive cell transfer |
| KR20230065251A (ko) | 2020-08-07 | 2023-05-11 | 네오진 테라퓨틱스 비.브이. | 유전적으로 조작된 t 세포를 풍부화시키기 위한 방법 |
| JP2024503515A (ja) * | 2021-01-20 | 2024-01-25 | ネオジン セラピューティクス ビー．ブイ． | 改変抗原提示細胞 |
| EP4298120A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2024058234A1 (ja) * | 2022-09-13 | 2024-03-21 | 株式会社サイト－ファクト | 移植用ｔ細胞およびその製造方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| AU6816194A (en) * | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
| EP0814838B1 (en) | 1995-03-08 | 2003-05-14 | The Scripps Research Institute | Antigen presenting system and activation of t-cells |
| EP0969865B1 (en) | 1996-05-23 | 2006-12-06 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
| CA2280997C (en) | 1997-03-11 | 2013-05-28 | Perry B. Hackett | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
| WO1999047687A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Enhanced anti-tumor immunity |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| US7955845B2 (en) * | 2001-11-20 | 2011-06-07 | Dana Farber Cancer Institute, Inc. | Modified antigen-presenting cells |
| US8227432B2 (en) | 2002-04-22 | 2012-07-24 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2672895T3 (es) * | 2005-08-05 | 2018-06-18 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | Generación de células T específicas de antígeno |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| BRPI1006215A2 (pt) | 2009-03-20 | 2019-09-24 | Genentech Inc | " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo " |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2851795C (en) * | 2011-10-20 | 2018-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| AU2015218239B2 (en) | 2014-02-14 | 2019-01-31 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
-
2015
- 2015-11-05 CN CN201580064711.8A patent/CN107207615A/zh active Pending
- 2015-11-05 HK HK18103028.0A patent/HK1243441A1/zh unknown
- 2015-11-05 EP EP15795304.3A patent/EP3215535A2/en not_active Withdrawn
- 2015-11-05 EP EP19152625.0A patent/EP3536707A1/en not_active Withdrawn
- 2015-11-05 KR KR1020177014630A patent/KR20170075785A/ko not_active Withdrawn
- 2015-11-05 WO PCT/US2015/059293 patent/WO2016073755A2/en not_active Ceased
- 2015-11-05 US US15/524,328 patent/US20170333480A1/en not_active Abandoned
- 2015-11-05 CA CA2964785A patent/CA2964785A1/en not_active Abandoned
- 2015-11-05 AU AU2015343013A patent/AU2015343013B2/en not_active Ceased
- 2015-11-05 JP JP2017543315A patent/JP2017535284A/ja not_active Withdrawn
-
2019
- 2019-11-08 JP JP2019203260A patent/JP2020022504A/ja active Pending
-
2020
- 2020-10-08 AU AU2020250247A patent/AU2020250247A1/en not_active Abandoned
-
2021
- 2021-07-09 US US17/371,924 patent/US20220072041A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535284A5 (OSRAM) | ||
| AU2017338827B2 (en) | HPV-specific binding molecules | |
| JP2019528769A5 (OSRAM) | ||
| Wilson et al. | Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| JP6868554B2 (ja) | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 | |
| JP2019511236A5 (OSRAM) | ||
| Zhang et al. | Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells | |
| JP2018531014A5 (OSRAM) | ||
| JP2016502512A5 (OSRAM) | ||
| JP2018504459A5 (OSRAM) | ||
| JP2024123133A (ja) | Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物 | |
| AU2018345539A1 (en) | HPV-specific binding molecules | |
| US12303540B2 (en) | RNA viruses for immunovirotherapy | |
| TW201827460A (zh) | 改善配對的ｔ細胞受體 | |
| SA517382216B1 (ar) | بروتينات دمج التعديل المناعي واستخداماتها | |
| JP2018509148A5 (OSRAM) | ||
| JP2017535292A5 (OSRAM) | ||
| JP2015518479A5 (OSRAM) | ||
| JP2018512856A5 (OSRAM) | ||
| KR20240006721A (ko) | 막 형질 전환 네오 안티젠 펩타이드 | |
| JP2019516665A5 (OSRAM) | ||
| JP2019530431A5 (OSRAM) | ||
| JP2018509163A5 (OSRAM) | ||
| JP2024051109A (ja) | インターロイキン２３受容体に特異的なキメラ抗原受容体 |